507 related articles for article (PubMed ID: 30341058)
21. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.
Kusumoto S; Tanaka Y; Ueda R; Mizokami M
J Gastroenterol; 2011 Jan; 46(1):9-16. PubMed ID: 20924616
[TBL] [Abstract][Full Text] [Related]
22. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
[TBL] [Abstract][Full Text] [Related]
23. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy.
Fidan S; Capkın E; Arıca DA; Durak S; Okatan IE
Int J Rheum Dis; 2021 Feb; 24(2):254-259. PubMed ID: 33244900
[TBL] [Abstract][Full Text] [Related]
24. Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation.
Lee J; Park JY; Kim DG; Lee JY; Kim BS; Kim MS; Il Kim S; Kim YS; Huh KH
Sci Rep; 2018 Oct; 8(1):15629. PubMed ID: 30353021
[TBL] [Abstract][Full Text] [Related]
25. Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B.
Lee HL; Jang JW; Han JW; Lee SW; Bae SH; Choi JY; Han NI; Yoon SK; Kim HJ; Lee S; Cho SG; Min CK; Kim DW; Lee JW
Dig Dis Sci; 2019 Oct; 64(10):2992-3000. PubMed ID: 30982209
[TBL] [Abstract][Full Text] [Related]
26. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital.
Fukuda W; Hanyu T; Katayama M; Mizuki S; Okada A; Miyata M; Handa Y; Hayashi M; Koyama Y; Arii K; Kitaori T; Hagiyama H; Urushidani Y; Yamasaki T; Ikeno Y; Suzuki T; Omoto A; Sugitani T; Morita S; Inokuma S
Arthritis Res Ther; 2019 Nov; 21(1):255. PubMed ID: 31779676
[TBL] [Abstract][Full Text] [Related]
27. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
Watanabe T; Fukae J; Fukaya S; Sawamukai N; Isobe M; Matsuhashi M; Shimizu M; Akikawa K; Tanimura K; Atsumi T; Koike T
Int J Rheum Dis; 2019 Apr; 22(4):574-582. PubMed ID: 30338649
[TBL] [Abstract][Full Text] [Related]
28. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.
Matsui T; Kang JH; Nojima M; Tomonari A; Aoki H; Yamazaki H; Yane K; Tsuji K; Andoh S; Andoh S; Sakai H; Maemori M; Maguchi H; Tanaka Y
J Med Virol; 2013 Nov; 85(11):1900-6. PubMed ID: 23926082
[TBL] [Abstract][Full Text] [Related]
29. [Latest Treatment of Viral Hepatitis--Overcoming Hepatitis C and Reactivation of Hepatitis B].
Tanaka Y
Rinsho Byori; 2016 Feb; 64(2):211-8. PubMed ID: 27311286
[TBL] [Abstract][Full Text] [Related]
30. HBsAg (-)/HBsAb (-)/HBeAg (-)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B-cell lymphoma receiving rituximab based immunochemotherapy.
Shui LP; Zhu Y; Duan XQ; Chen YT; Yang L; Tang XQ; Zhang HB; Xiao Q; Wang L; Liu L; Luo XH
J Med Virol; 2023 Feb; 95(2):e28549. PubMed ID: 36734081
[TBL] [Abstract][Full Text] [Related]
31. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
[TBL] [Abstract][Full Text] [Related]
32. High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy.
Chang WY; Chiu YC; Chiu FW; Hsu YC; Tseng TC; Cheng PN; Yang SS; Liu CJ; Su TH; Yang HC; Liu CH; Chen PJ; Chen DS; Kao JH
J Infect Dis; 2020 Sep; 222(8):1345-1352. PubMed ID: 32396638
[TBL] [Abstract][Full Text] [Related]
33. Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma.
Guarino M; Picardi M; Vitello A; Pugliese N; Rea M; Cossiga V; Pane F; Caporaso N; Morisco F
Ann Hepatol; 2017; 16(2):198-206. PubMed ID: 28233742
[TBL] [Abstract][Full Text] [Related]
34. Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.
Viganò M; Mangia G; Lampertico P
Expert Opin Biol Ther; 2014 Jul; 14(7):1019-31. PubMed ID: 24909454
[TBL] [Abstract][Full Text] [Related]
35. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
[TBL] [Abstract][Full Text] [Related]
36. Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study.
Tsai YF; Yang CI; Du JS; Lin MH; Tang SH; Wang HC; Cho SF; Liu YC; Su YC; Dai CY; Hsiao HH
PeerJ; 2019; 7():e7481. PubMed ID: 31565551
[TBL] [Abstract][Full Text] [Related]
37. High rate of hepatitis B viral breakthrough in elderly non-Hodgkin lymphomas patients treated with Rituximab based chemotherapy.
Castelli R; Ferraris L; Pantaleo G; Lambertenghi Deliliers G; Cicardi M
Dig Liver Dis; 2016 Nov; 48(11):1394-1397. PubMed ID: 27590841
[TBL] [Abstract][Full Text] [Related]
38. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.
Chen LF; Mo YQ; Jing J; Ma JD; Zheng DH; Dai L
Int J Rheum Dis; 2017 Jul; 20(7):859-869. PubMed ID: 28160426
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
[TBL] [Abstract][Full Text] [Related]
40. [Prevention of hepatitis B virus reactivation in B-cell lymphoma patients receiving chemotherapy with rituximab].
Mimura N; Kojima H; Tsujimura H; Ise M; Sakai C; Fukai K; Yokosuka O; Kumagai K
Rinsho Ketsueki; 2010 Mar; 51(3):213-5. PubMed ID: 20379117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
